China · Delayed Price · Currency is CNY Getein Biotech Statistics
Total Valuation
Getein Biotech has a market cap or net worth of CNY 4.17 billion. The enterprise value is 2.89 billion.
| Market Cap | 4.17B |
| Enterprise Value | 2.89B |
Important Dates
The last earnings date was Wednesday, October 28, 2026.
| Earnings Date | Oct 28, 2026 |
| Ex-Dividend Date | Sep 18, 2026 |
Share Statistics
Getein Biotech has 506.44 million shares outstanding. The number of shares has decreased by -0.88% in one year.
| Current Share Class | 506.44M |
| Shares Outstanding | 506.44M |
| Shares Change (YoY) | -0.88% |
| Shares Change (QoQ) | -4.52% |
| Owned by Insiders (%) | 40.84% |
| Owned by Institutions (%) | 2.82% |
| Float | 282.75M |
Valuation Ratios
The trailing PE ratio is 14.20.
| PE Ratio | 14.20 |
| Forward PE | n/a |
| PS Ratio | 3.75 |
| PB Ratio | 1.44 |
| P/TBV Ratio | 1.53 |
| P/FCF Ratio | 12.97 |
| P/OCF Ratio | 9.43 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 7.87, with an EV/FCF ratio of 8.98.
| EV / Earnings | 9.88 |
| EV / Sales | 2.59 |
| EV / EBITDA | 7.87 |
| EV / EBIT | 10.06 |
| EV / FCF | 8.98 |
Financial Position
The company has a current ratio of 3.84, with a Debt / Equity ratio of 0.09.
| Current Ratio | 3.84 |
| Quick Ratio | 3.10 |
| Debt / Equity | 0.09 |
| Debt / EBITDA | 0.75 |
| Debt / FCF | 0.86 |
| Interest Coverage | 33.04 |
Financial Efficiency
Return on equity (ROE) is 10.07% and return on invested capital (ROIC) is 15.68%.
| Return on Equity (ROE) | 10.07% |
| Return on Assets (ROA) | 4.77% |
| Return on Invested Capital (ROIC) | 15.68% |
| Return on Capital Employed (ROCE) | 9.41% |
| Weighted Average Cost of Capital (WACC) | 4.57% |
| Revenue Per Employee | 642,921 |
| Profits Per Employee | 168,796 |
| Employee Count | 1,733 |
| Asset Turnover | 0.30 |
| Inventory Turnover | 1.93 |
Taxes
In the past 12 months, Getein Biotech has paid 29.36 million in taxes.
| Income Tax | 29.36M |
| Effective Tax Rate | 9.12% |
Stock Price Statistics
The stock price has decreased by -5.61% in the last 52 weeks. The beta is 0.08, so Getein Biotech's price volatility has been lower than the market average.
| Beta (5Y) | 0.08 |
| 52-Week Price Change | -5.61% |
| 50-Day Moving Average | 9.19 |
| 200-Day Moving Average | 9.02 |
| Relative Strength Index (RSI) | 33.47 |
| Average Volume (20 Days) | 8,297,941 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Getein Biotech had revenue of CNY 1.11 billion and earned 292.52 million in profits. Earnings per share was 0.58.
| Revenue | 1.11B |
| Gross Profit | 756.99M |
| Operating Income | 287.33M |
| Pretax Income | 321.88M |
| Net Income | 292.52M |
| EBITDA | 365.63M |
| EBIT | 287.33M |
| Earnings Per Share (EPS) | 0.58 |
Balance Sheet
The company has 1.66 billion in cash and 277.28 million in debt, with a net cash position of 1.39 billion or 2.74 per share.
| Cash & Cash Equivalents | 1.66B |
| Total Debt | 277.28M |
| Net Cash | 1.39B |
| Net Cash Per Share | 2.74 |
| Equity (Book Value) | 3.01B |
| Book Value Per Share | 5.91 |
| Working Capital | 1.82B |
Cash Flow
In the last 12 months, operating cash flow was 442.65 million and capital expenditures -120.87 million, giving a free cash flow of 321.78 million.
| Operating Cash Flow | 442.65M |
| Capital Expenditures | -120.87M |
| Depreciation & Amortization | 78.30M |
| Net Borrowing | -353.99M |
| Free Cash Flow | 321.78M |
| FCF Per Share | 0.64 |
Margins
Gross margin is 67.94%, with operating and profit margins of 25.79% and 26.25%.
| Gross Margin | 67.94% |
| Operating Margin | 25.79% |
| Pretax Margin | 28.89% |
| Profit Margin | 26.25% |
| EBITDA Margin | 32.82% |
| EBIT Margin | 25.79% |
| FCF Margin | 28.88% |
Dividends & Yields
This stock pays an annual dividend of 0.30, which amounts to a dividend yield of 3.64%.
| Dividend Per Share | 0.30 |
| Dividend Yield | 3.64% |
| Dividend Growth (YoY) | 66.67% |
| Years of Dividend Growth | n/a |
| Payout Ratio | 56.73% |
| FCF Payout Ratio | 47.22% |
| Buyback Yield | 0.88% |
| Shareholder Yield | 4.52% |
| Earnings Yield | 7.04% |
| FCF Yield | 7.71% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |
| Graham Formula Value | |
| Graham Formula Upside |
Stock Splits
The last stock split was on June 8, 2022. It was a forward split with a ratio of 1.4.
| Last Split Date | Jun 8, 2022 |
| Split Type | Forward |
| Split Ratio | 1.4 |
Scores
Getein Biotech has an Altman Z-Score of 5.85 and a Piotroski F-Score of 7.
| Altman Z-Score | 5.85 |
| Piotroski F-Score | 7 |